Medable

With more than 50% of trials expected to be decentralized by 2024, many sponsors and CROs are learning that decentralizing clinical trials is not just for a pandemic. But despite adoption, there are still questions, myths, and rumors about what it means to “decentralize a trial”.
Listen in as experts from Medable and Incyte compare traditional trials (design first, patient second) with patient-centered trials (patient first, design second) and discuss how adopting a decentralized approach can help any organization, regardless of size or therapeutic areas focus, reimagine their existing approach to choreograph a masterfully designed patient-centered trial.




In this on-demand webinar, you will learn:


The fundamentals of decentralized clinical trials

Use cases for hybrid and fully decentralized approaches

Benefits of designing patient-centered clinical trials

Pharma Sponsors, Biotechs companies, CROs, University Research heads

Clinical operations / development professionals

Founder/ President/ CEO/ Executive Directors

Chief Medical Officers / Chief Scientific Officers/ Chief Innovation Officers

Clinical trial strategy team professionals

Worked in the industry for over 25 years across all phases of clinical development in multiple sectors including Big Pharma (GSK, Pfizer, Novartis, Bayer), Biotech (Alnylam, Lexicon) and within the CRO space (Quintiles/IQVIA, Covance/LabCorp). Over the past 15 years have led Global teams in Project Management (Cardiovascular/Metabolic), Project Costing and Operational Strategy & Design and been instrumental in seeking, designing, and executing innovative solutions for client portfolios to meet the evolving and future needs of drug development. In her role within Medable, Claire will be collaborating with our clients and internal teams to shape DCT solutions that are designed around the patient to optimise inclusivity and operational efficiency to transform drug development and registration.




Senior Medical Director, US Medical Affairs
Incyte

Dr. John Galvin MD, MS, MPH is a hematologist in Chicago, IL and is Senior Medical Director, US Medical Affairs for Incyte Pharmaceuticals. Dr. Galvin is also affiliated with the University of Illinois Cancer Center. He has been in practice 11 years. He also has an affiliation with Northwestern University’s department of Immunology & Microbiology. He specializes in hematologic oncology with a focus on stem cell transplantation and graft versus host disease.

Webcasts

Thursday, October 20, 2022 at 11 AM EDT | 10 AM CDT | 8 AM PDT

It’s no secret that hybrid and decentralized trials (DCT) are here to stay. Make sure your organization is ready for the shift towards clinical trials that put patients first.

Everything you need to know about hybrid/decentralized trials

Articles

Why eConsent Primes Patients and Studies for Success 

Patient recruitment, retention, diversity, & safety are all factors driving the need for radical innovation in clinical research. This need was made painfully apparent during the current COVID-19 pandemic. 

We can no longer ‘do the same thing and expect a different result’; it’s time to take giant steps forward. 

Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. 

Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now.

The Centricity of Decentricity

Over 70% of potential research participants live >2 hours away from a research site, & patient drop-out rates can reach 30% depending on the therapeutic area.

The Solution: Medable eConsent

Why?
1. Medable eConsent enables the enrollment of underrepresented, diverse populations through remote consenting. 
2. Medable eConsent has proven to reduce screening timelines by 50%, & increase patient engagement by 15%+.


Tips for Tailoring eConsent for Optimal Patient Centricity

A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today.

The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). 

Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.